

Step-by-step guide

How to evaluate an Initial CTA RMS selection

CTIS Training Programme – Module 06 Version 1.1 – November 2021

Learning Objectives

• Understand the Reporting Member State (RMS) selection process for a multinational CTA.



© European Medicines Agency, 2022

Reproduction and/or distribution of the content of these training materials for non-commercial or commercial purposes is authorised, provided the European Medicines Agency is acknowledged as the source of the materials.

The European Medicines Agency developed this training material to enhance public access to information on the Clinical Trial Information System (CTIS). This material describes a preliminary version of CTIS and may therefore not entirely describe the system as it is at the time of use of this material. The Agency does not warrant or accept any liability in relation to the use (in part or in whole) or the interpretation of the information contained in this training material by third parties.

Selection of the Reporting Member State

The main purpose of the **Reporting Member State (RMS)** selection process is to select a Member State Concerned (MSC) for the **trial life cycle** that will play a **leading role during the evaluation**. The RMS leads the evaluation, raises and consolidates considerations during the validation and Part I assessment phases, and issues the conclusion on part I.

There are two main actors involved in the RMS selection process:

- Sponsors: Propose an MSC to be the RMS in the application dossier.
- **MSCs:** Express willingness/unwillingness to become the RMS and discuss amongst them which MSC should be the RMS.

In the case of multinational trials, the RMS is proposed by the sponsor at the time of submission of an initial application dossier and is finally assigned to an MSC after the completion of the RMS selection tasks by all MSCs. In a mononational trial, the RMS is assigned to the only MSC selected by the sponsor in the application.

The RMS selection process **is triggered as soon as the initial application dossier is submitted** by the sponsor. This process runs in parallel to the validation phase. However, an RMS needs to be selected to be able to complete this phase, as the RMS is responsible for consolidating the considerations made by the MSCs and submitting the validation conclusion. The selection of the RMS can occur within **6 days after the submission** of the application dossier by the sponsor, in line with Article 5(1) of the Regulation (EU) No 536/2014 on Clinical Trials (CT Regulation).

This step-by-step guide outlines the different scenarios withing the RMS selection process and examples of possible scenarios.



Evaluation of a CTA

The evaluation process starts **once the sponsor has submitted an initial Clinical Trial Application (CTA).** The MSCs can **evaluate the documentation** provided by the sponsor to ensure the compliance with the CT Regulation. The evaluation is performed for the following types of CTAs: Initial CTA, Substantial Modification (SM) and Additional MSC CTA (Add MSC).

EVALUATION OF A CLINICAL TRIAL APPLICATION



Focus of this document.

Content included in module 06 eLearning | Step-by-step guide RMS selection.

Content included in module 08 Quick guide | Step-by-step guide SM | Step-by-step guide Add MSC.

Step in the process that may occur depending on the CTA submitted. An SM CTA can include Part I and Part II, Part I only or Part II only. For an Add MSC CTA users may rise considerations.

*In case of applications limited to Part I, the sponsor has two years from the notification of the conclusion of Part I to submit an application limited to Part II.



RMS selection overview

The different scenarios within the RMS selection process for multinational and mononational clinical trials are shown below:

RMS selection Mononational clinical trials

The MSC is appointed RMS

RMS selection Multinational clinical trials



Scenario 2.2: Issue disagreement with the candidate RMS

Example of an RMS selection process with 3 MSCs (Austria, Germany, and Greece).

 All MSCs can view the 'Express Willingness/Unwillingness' task in the 'Task' tab by entering the EU CT ID or using the 'Advance search'. Then, they can assign the task to users, using the appropriate button on the right side of the task.

	Clinical trials	Notices & alerts (•	Tasks A	d hoc assessmer	nts Annua	al safety repo	rting Ins _l	pections l	Jnion control	
	۹				(8 SEAR	сн	ŗ	Advanced Sea	arch 🕶	
Ex Wi	press Illingness/unwil ending 2021-5013	lingness 195-28-00	RMS:	Application and Non- SM type: INITIAL	Sponsor/Co- sponsors: Test Organisation	Evaluation process: Validation	Created: 31/08/2021	Due: 03/09/2021	Remaining days: 3	Assignee:	9

 Once in the Express willingness page, all MSCs can click on the blue 'Pending' label to express willingness or unwillingness.

CTIS Training Under evaluation			Due dat	xpress willingnes e:09/09/2021 View trial	SS Assigned details				
Sponsor : Test Organisation	iponsor : Test Organisation Product being tested Marketing Authorisation Active substance name								
Product being teste	a Marketing Au	itnorisation /	Active substance name						
IMP1 Irbesartan 300 mg ta	blets Yes	1	Irbesartan						
Summary									
MSC	Current willing	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)				
AUSTRIA Proposed RMS	Pending	-	90	57	63.333 %				
GERMANY	Pending	-	206	110	53.398 %				
GREECE	Pending	-	365	78	21.370 %				

3. The MSCs can select one of the radio buttons '**Willing**' or '**Unwilling**' and then they can select the '**Share'** button in order to enable the '**Complete'** button. Once the task is completed, it will be visible for the other MSCs. *In this example there are 2 willing MSCs and 1 unwilling MSC.*

MSC 1 AUS	TRIA:	×	MSC 2 GER	RMANY:	×
Express willingness to be RMS	O Willing	○ Unwilling	Express willingness to be RMS	○ Willing	O Unwilling
Justification			Justification		
		CANCEL ✓ Share			CANCEL Share
MSC 3 GRE	ECE:	×			
Express willingness to be RMS	○ Willing	O Unwilling			
Justification			[+ Create subtask	✓ Complete
		CANCEL ✓ Share			



In case an MSC (including the Proposed RMS) **does not express willingness or unwillingness** in the system, **the default value at the end of day 3** will be set for as '**Unwilling'**. If the proposed RMS selects 'Unwilling' a **justification must be included.** If more than one MSC are simultaneously working on the same process, they will have to **refresh the page** to see the latest updates.

5

Scenario 2.2: Issue disagreement with the candidate RMS

4. If by the end of day 3 or earlier there is more than one MSC willing to be the RMS, **the MSC** with the lowest workshare out of those willing to be the RMS will become the assignor.

Summary						Assignoi selected
MSC	MSC willing at end of day 3	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)	by the
GERMANY Assignor	willing	-	206	110	53.398 %	system
GREECE	unwilling	-	365	78	21.370 %	Propose
AUSTRIA Proposed RMS	willing	-	90	57	63.333 %	RMS by
						the
						sponsor

5. The MSCs can find the 'Agree RMS' task available on the 'Tasks' tab and assign it to a user.

Agree RMS Pending 2021-501396-84-00	Application S: and Non- SM type:	Sponsor/Co- sponsors:	Evaluation process:	Created:	Due:	Remaining days:	Assignee:	
	INITIAL	Test Organisation	Validation	31/08/2021	07/09/2021	7		θ

 The MSCs are encouraged to express their comments prior to the election of the candidate RMS in the 'Discussion with MSCs' section and then they can click on the 'Share comment' button.

Discussion with MSCs			
Greece			
			Share comment

7. The assignor (i.e. Germany) can **select the candidate RMS** among the willing MSCs. *In this example, the assignor has selected Germany as the candidate RMS.*

Proposed RMS @ Assignor @ Candidate RMS by assignor @ RMS AUSTRIA GERMANY	RMS selection			
AUSTRIA GERMANY GERMANY	Proposed RMS 🚱	Assignor 🔞	Candidate RMS by assignor 🕑	RMS
	AUSTRIA	GERMANY	GERMANY ~ -	-

8. The users can **disagree with the candidate RMS** selected by the assignor by including a justification and clicking on the **'Issue disagreement'** button.

9. If there is a disagreement on the choice of the candidate RMS, the **proposed RMS** (i.e. Austria) **will become the RMS**.



RMS selection

scenarios

If the MSCs (including the candidate RMS) do **not express their agreement/ disagreement**, the candidate RMS selected by the assignor will be appointed.

The disagreement is not possible before assignor has made an **active selection**.

The assignor cannot issue disagreement 6 with its own selection.

Scenario 2.3: Assignor doesn't select a candidate RMS

Example of an RMS selection process with 3 MSCs (Austria, Germany and Greece).

 All MSCs can view the 'Express Willingness/Unwillingness' task in the 'Task' tab by entering the EU CT ID or using the 'Advance search'. Then, they can assign the task to users, using the appropriate button on the right side of the task.

Clinical trials	Notices & alerts 🕕	Tasks	Ad hoc assessmen	ts Annua	il safety repoi	ting Ins _l	pections l	Jnion control	
٩			6	SEAR	сн	P	Advanced Sea	arch 🕶	
Express willingness/unw Pending 2021-501	illingness RMS 395-28-00	Application and Non- SM type: INITIAL	Sponsor/Co- sponsors: Test Organisation	Evaluation process: Validation	Created: 31/08/2021	Due: 03/09/2021	Remaining days: 3	Assignee:	θ

 Once in the Express willingness page, all MSCs can click on the blue 'Pending' label to express willingness or unwillingness.

CTIS Training	Under evaluation		E>	cop/op/2021 View trial	SS Assigned details						
Sponsor : Test Organisation Product being test	Sponsor : Test Organisation Product being tested Marketing Authorisation Active substance name										
IMP1 Irbesartan 300 mg ta	ablets Yes	I	rbesartan								
Summary											
MSC	Current willing	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)						
AUSTRIA Proposed RMS	Pending	-	90	57	63.333 %						
GERMANY	Pending	-	206	110	53.398 %						
GREECE	Pending	-	365	78	21.370 %						

3. The MSCs can select one of the radio buttons **`Willing**' or **`Unwilling**' and then they select the **`Share'** button in order to enable the **`Complete'** button. *In this example there are 2 willing MSCs and 1 unwilling MSC.*

MSC 1 AUS	TRIA:	×	MSC 2 GERMANY:	
xpress willingness to be MS	O Willing	⊖ Unwilling	Express willingness to be O Willing	○ Unwilling
ustification			Justification	
		CANCEL Share	i i	CANCEL Sha
MSC 3 GRE	ECE:	×		
Express willingness to be RMS	○ Willing	O Unwilling		
Justification			+ Create subtask	✓ Complete
		CANCEL ✓ Share		



In case an MSC (including the Proposed RMS) **does not** express willingness or unwillingness in the system, the default value at the end of day 3 will be set for as 'Unwilling'.

Scenario 2.3: Assignor doesn't select a candidate RMS

4. If by the end of day 3 or earlier there is more than one MSC willing to be the RMS, **the MSC** with the lowest workshare out of those willing to be the RMS will become the assignor.

Summary						Assigno selected
MSC	MSC willing at end of day 3	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)	by the
GERMANY Assignor	willing	-	206	110	53.398 %	system
GREECE	unwilling	-	365	78	21.370 %	Propose
AUSTRIA Proposed RMS	willing	-	90	57	63.333 %	RMS by
						the sponso

5. The MSCs can find the **'Agree RMS'** task available on the **'Tasks'** tab and then they can select the **'Assign to me'** button.

Agree RMS Pending 2021-501396-84-00	RMS:	Application and Non- SM type:	Sponsor/Co- sponsors:	Evaluation process:	Created:	Due:	Remaining days:	Assignee:	
		INITIAL	Test Organisation	Validation	31/08/2021	07/09/2021	7		θ
IMP1: Irbesartan 300 mg tablets · IR	BESART	AN							

 The MSCs are encouraged to express their comments prior to the election of the candidate RMS in the 'Discussion with MSCs' section and then they can click on the 'Share comment' button.

Discussio	on with MSCs	
Greece		
		Share comment

7. If the assignor (i.e. Germany) **does not select a candidate RMS** among the willing MSC, the **proposed RMS** (i.e. Austria) **will become the RMS** at the end of day 6.



RMS selection

scenarios

Scenario 3.1: Assignor selects a candidate RMS after MSCs re-express willingness/unwillingness

Example of how to re-express willingness or unwillingness and agree on the RMS with 3 MSCs (Austria, Germany and Greece).

 All MSCs can view the 'Express Willingness/Unwillingness' task in the 'Task' tab by entering the EU CT ID or using the 'Advance search'. Then, they can assign the task to users, using the appropriate button on the right side of the task.

	Clinical trials	Notices & alerts 🕕	Tasks A	d hoc assessmen	its Annua	il safety repoi	rting Insp	oections (Jnion control	
	Q			(SEAR	сн	Д	dvanced Se	arch 🕶	
E: W	xpress illingness/unwilli	ingness RMS	Application and Non-	Sponsor/Co- sponsors:	Evaluation process:	Created:	Due:	Remaining days:	Assignee:	
e	rending 2021-50139	13-20-00	INITIAL	Test Organisation	Validation	31/08/2021	03/09/2021	3		0

2. Once in the Express willingness page, all MSCs can click on the blue **'Pending'** label to express willingness or unwillingness. *In this example, none of the MSCs express willing or unwilling.*

	Under evaluation		E Ex	press willingne	Assigned		
			Due dat				
Sponsor : Test Organisation Product being test	onsor : Test Organisation Product being tested Marketing Authorisation Active substance name						
IMP1 Irbesartan 300 mg ta	ablets Yes	I	rbesartan				
Summary							
MSC	Current willing	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)		
AUSTRIA Proposed RMS	Pending	-	90	57	63.333 %		
GERMANY	Pending	-	206	110	53.398 %		
GREECE	Pending	-	365	78	21.370 %		

3. If **no MSC is willing to be the RMS by the end of day 3**, all MSCs can **re-express willingness or unwillingness** until day 5. They can select the **'Assign to me'** button on the right side of the 'Re-express willingness/unwillingness and agree RMS' task.

	Clinical trials	Notices & alerts (0 Ta	sks Ad	d hoc assessments	Annual sa	afety reportin	g Inspec	tions Un	on control
	Q				ø	SEARCH		Adv	vanced Seare	ch •
Re wi ar	e-express illingness/unwill nd agree RMS ending) 2021-5013	ingness 195-28-00 (RMS:	Applicat and No SM typ INITIA	tion Sponsor/Co- on- sponsors: AL Panpharma	Evaluation process: Validation	Created: 30/07/2021	Due: 03/08/2021	Remaining days: -	Assignee:



In case an MSC (including the Proposed RMS) **does not** express willingness or unwillingness in the system, the default value at the end of day 3 will be set for as 'Unwilling'.

Scenario 3.1: Assignor selects a candidate RMS after MSCs re-express willingness/unwillingness

4. Once in the re-express willingness/unwillingness and agree RMS page, all MSCs can click on the blue **'Pending'** label to re-express willingness or unwillingness.

CTIS Trainin	g Under evaluation	l	E Re-express willi Assigned Due date: 06/08/2021	ngness/unwillingne View trial details	ess and agree RMS
Sponsor : Test Organisation	and Manhadian And				
Product being te	ested Marketing Au	thorisation	Active substance name		
IMP1 Irbesartan 300 m	g tablets Yes	1	Irbesartan		
Summary					
MSC	Re-Express Willing	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)
AUSTRIA Assignor	Pending. It is only possible to re-express willingness until	-	90	57	63.333 %
GERMANY	Pending	-	206	110	53.398 %
GREECE	Pending		365	78	21.370 %

5. The MSCs can select one of the radio buttons '**Willing**' or '**Unwilling**' and then they can select the '**Share'** button in order to enable the '**Complete'** button. *In this example there are 2 willing MSCs and 1 unwilling MSC.*

MSC 1 AUST	RIA:	×	MSC 2 GER	MANY:	×
Express willingness to be RMS	○ Willing	O Unwilling	Express willingness to be RMS	 Willing 	 Unwilling
Justification			Justification		
		CANCEL Share			CANCEL Share
MSC 3 GRE	ECE:	×			
Express willingness to be RMS	○ Willing	O Unwilling	+ 0	aata cubtack	Complete
Justification					
		CANCEL Share			



If no MSC was willing in the initial 'express willingness or unwillingness' task, MSCs can **re-express** their willingness **before** the RMS selection **expiration date** to allow the assignor to re-select an RMS. If no MSC reexpress willingness or unwillingness the assignor will be the proposed RMS. If no MSC reexpress willingness or 10 unwillingness the assignor will be the proposed RMS.

Scenario 3.1: Assignor selects a candidate RMS after MSCs re-express willingness/unwillingness

6. If by the end of day 5 or earlier there is more than one MSC willing to be the RMS, **the MSC** with the lowest workshare out of those willing to be the RMS will become the assignor.

Summary						Assignoi selected
MSC	MSC willing at end of day 3	Justification	Number of trials (MSC)	Number of trials (RMS)	Workshare % (YTD)	by the
GERMANY Assignor	willing	-	206	110	53.398 %	system
GREECE	unwilling	-	365	78	21.370 %	Propose
AUSTRIA Proposed RMS	willing	-	90	57	63.333 %	RMS by
						the
						(sponso

7. The MSCs can find the **'Agree RMS'** task available on the 'Tasks' tab and then they can assign the task to users, using the appropriate button on the right side of the task.

Agree RMS Pending 2021-501396-84-00 R	Application MS: and Non- SM type:	Sponsor/Co- sponsors:	Evaluation process:	Created:	Due:	Remaining days:	Assignee:		
	INITIAL	Test Organisation	Validation	31/08/2021	07/09/2021	7		Θ	
									Ē

IMP1: Irbesartan 300 mg tablets · IRBESARTAN

8. The MSCs can express their comments regarding the candidate RMS in the **'Discussion with MSCs'** section.

RMS selection			
Proposed RMS 🖗 AUSTRIA	Assignor @ GERMANY	Candidate RMS by assignor	RMS
Discussion with MSCs			
			Share comment

9. Then the assignor (i.e. Germany) can **select the candidate RMS** among the willing MSC. *In this example, the assignor has selected Germany as the candidate RMS.*

RMS selection				
Proposed RMS 🚱	Assignor 😧	Candidate RMS by assignor 😧		RMS
AUSTRIA	GERMANY	GERMANY	~	

10. If there isn't a disagreement on the choice of the candidate RMS, the candidate RMS (i.e. Germany) will become the RMS at the end of day 6.



In case of disagreement with the candidate selected by the assignor, the proposed RMS will become the RMS. If no disagreement is issued, **the candidate RMS proposed by the assignor will become the RMS.**

If **no action is taken by the assignor**, the proposed RMS (by the sponsor) will become the RMS.

European Medicines Agency

Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands Telephone +31 (0)88 781 6000 Send a question www.ema.europa.eu/contact

Clinical Trials Information System (CTIS) Step-by-step guide: How to evaluate a CTA - RMS selection

© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.